February 19, 2025
Glucagon Like Peptide 1 Analogs Market

The rising adoption of once-weekly GLP-1 injections is anticipated to openup the new avenue for Glucagon Like Peptide 1 Analogs Market

Market Overview:

Glucagon-like peptide-1 (GLP-1) analogs are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLP-1 analogs work by stimulating the pancreas to release more insulin when blood sugar levels are high and by suppressing glucagon secretion. They also slow gastric emptying and reduce appetite. The commonly used GLP-1 analogs are exenatide, liraglutide, dulaglutide, albiglutide, semaglutide, and lixisenatide. They are available in both injectable pen devices and weekly or monthly injections to provide continuous blood sugar control.

The Glucagon-like Peptide-1 (GLP-1) Analogs Market is estimated to be valued at US$ 11.87 Bn or Billion in 2023 and is expected to exhibit a CAGR of 1.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The rise in prevalence of diabetes is one of the major drivers of the GLP-1 analogs market. According to the International Diabetes Federation, in 2021, approximately 537 million adults were living with diabetes across the globe and the number is expected to rise to 643 million by 2030 and 783 million by 2045. Growing diabetic population has increased the demand for efficient management of blood glucose levels, thus fueling the adoption of GLP-1 analogs. Additionally, rising awareness regarding the gastrointestinal side effects of other diabetic drug classes is prompting physicians and patients to prefer GLP-1 analogs due to their better tolerability profile. The availability of once-weekly formulations of GLP-1 analogs providing continuous glucose control throughout the week has further strengthened the market as it enhances patient convenience and compliance to treatment.

Segment Analysis

The global Glucagon Like Peptide 1 Analogs market is segmented based on drug class, application, distribution channel and region. Based on drug class, the market is segmented into exenatide, liraglutide, lixisenatide, dulaglutide and albiglutide. Among these, liraglutide segment dominates the market owing to its efficacy and longer duration of action. Based on application, the market is categorized into type 2 diabetes, obesity and other applications. Type 2 diabetes segment holds the largest market share due to high prevalence of diabetes globally.

PEST Analysis

Political: Governments across countries are supporting various initiatives to spread awareness about diabetes and obesity. Various regulations have also been introduced for marketing and sale of GLP-1 analog drugs.
Economic: Rising healthcare expenditure coupled with growing per capita income is fueling the growth of GLP-1 analogs market globally.
Social: Increasing sedentary lifestyle and unhealthy eating habits have led to surge in cases of diabetes and obesity, driving demand for alternative treatment options like GLP-1 analogs.
Technological: Continuous R&D efforts by key players for development of superior drug delivery systems and novel formulations are expected to offer new opportunities over the forecast period.

Key Takeaways

The Global Glucagon Like Peptide 1 Analogs Market Size is expected to witness high growth, exhibiting a CAGR of 1.1% over the forecast period, due to increasing prevalence of diabetes globally. Regionally, North America dominates the market owing to presence of major players and increasing awareness regarding GLP-1 therapies in the region. Europe also holds significant share in the market driven by growing geriatric population prone to diabetes.

The type 2 diabetes segment accounts for the largest share in the Glucagon Like Peptide 1 Analogs market due to high usage of GLP-1 analogs for management of blood glucose levels in diabetes patients. Key players operating in the Glucagon-like Peptide-1 (GLP-1) Agonists Market includes AstraZeneca, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer Inc. AstraZeneca’s Bydureon holds the leading position with increased patient acceptance and marketing efforts by the company. Eli Lilly and Company’s Trulicity also has strong foothold in the market.

Key players operating in the Glucagon-like Peptide-1 (GLP-1) Agonists Market are AstraZeneca, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer Inc. AstraZeneca dominates the liraglutide segment with its product Bydureon while Eli Lilly and Company has a significant share with its GLP-1 analog Trulicity.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →